ABSTRACT: Thiosemicarbazones play a pivotal role as potential therapeutic agents for the management of lung cancer. 4-(4-Cyanophenyl)-1-[(5-arylfuran-2-yl)methylene]thiosemicarbazides (1-10) were obtained via the reaction of 4-(4-cyanophenyl)thiosemicarbazide with 5-arylfurfurals. MTT assay was performed to assess their cytotoxic effects on A549 human lung adenocarcinoma and L929 mouse fibroblast cell lines. Compounds 1, 5, 6 and 7 were identified as the most effective anticancer agents on A549 cell line with IC50 values of 12.75±0.35 µg/mL, 4.30±0.61 µg/mL, 5.50±2.12 µg/mL and 5.90±0.57 µg/mL, respectively compared to cisplatin (IC50= 12.00±0.71 µg/mL). The IC50 values of these compounds for L929 cell line were higher than their IC50 values for A549 cell line indicating that their anticancer effects were selective. The apoptotic effects of these compounds were also analyzed based on Annexin V-PI binding capacities in flow cytometry. According to flow cytometric analyses, the early apoptotic effects of compounds 1, 5, 6 and 7 on A549 cell line were determined as 4.7, 5.1, 7.3 and 5.1%, whereas their late apoptotic effects were determined as 3.7, 2.0, 4.9 and 3.3%, respectively. Compound 6 showed more apoptotic activity than compounds 1, 5 and 7. According to these findings, compounds 5 and 6 stand out as promising anticancer agents for further in vitro and in vivo studies.
. INTRODUCTION
Lung cancer remains the leading cause of cancer-related death across the globe with a 5-year survival rate of less than 15% [1, 2] . As the most common lung cancer, non-small cell lung cancer (NSCLC) poses a major threat to public health. Despite substantial advances in diagnostic and therapeutic approaches, the overall survival for NSCLC patients still remains poor [3] . One main impediment for the treatment of NSCLC is that most patients are diagnosed at advanced or metastatic stages (stage III/IV) when the prognosis is poor and therapeutic options are limited [2] [3] [4] .
Apoptosis is a tightly regulated cellular process that is essential for removal of damaged or unwanted cells and maintenance of cellular homeostasis [5, 6] . In pathological conditions, particularly cancer, cells lose their ability to undergo apoptosis leading to uncontrolled proliferation [7] . Mounting evidence has shown that most of the anticancer agents trigger the induction of apoptosis and related cell death networks to eliminate tumor cells [7] and therefore the discovery of new apoptosis-inducing antitumor agents [8] is of great importance for the management of many types of cancer including lung cancer [6] [7] [8] [9] [10] .
Thiosemicarbazones (TSCs) have attracted a great deal of attention for many years owing to their pharmacological utility as therapeutic agents and versatility as ligands allowing them to give rise to a great variety of coordination modes [11, 12] . In particular, TSCs have been identified as promising antiproliferative agents against a variety of tumors through the inhibition of diverse molecular targets including ribonucleotide reductase (RNR) [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Among them, triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone, 3-AP), a potent RNR inhibitor, is an anticancer agent currently in clinical trials ( Figure 1 ) [11] [12] [13] [14] . On the basis of the aforementioned findings and in the continuation of our ongoing research efforts to identify new thiosemicarbazone derivatives as anticancer agents [18] [19] [20] , herein we reported the preparation of a new series of thiosemicarbazones and focused on their cytotoxic effects on A549 human lung adenocarcinoma and L929 mouse fibroblast cell lines. The most active compounds were also evaluated for their apoptotic effects on A549 cell line.
RESULTS AND DISCUSSION
The synthesis of thiosemicarbazone derivatives (1-10) was carried out according to the steps depicted in Figure 2 . In the initial step, 4-(4-cyanophenyl)thiosemicarbazide was synthesized via the reaction of 4-cyanophenyl isothiocyanate with hydrazine hydrate. The reaction of 4-(4-cyanophenyl)thiosemicarbazide with 5-arylfurfurals afforded 4-(4-cyanophenyl)-1-[(5-arylfuran-2-yl)methylene]thiosemicarbazides (1-10). The IR, 1 H NMR, 13 C NMR, and HRMS data were in agreement with the proposed structures of compounds 1-10. MTT assay was performed to determine the antiproliferative effects of compounds 1-10 on A549 human lung adenocarcinoma cell line. Compounds 5, 6 and 7 were more effective on A549 cell line than cisplatin, whereas compound 1 showed similar anticancer activity against A549 cell line compared to cisplatin (IC50= 12.00±0.71 µg/mL). IC50 Values of compounds 1, 5, 6 and 7 for A549 cell line were found as 12.75±0.35 µg/mL, 4.30±0.61 µg/mL, 5.50±2.12 µg/mL and 5.90±0.57 µg/mL, respectively. This outcome pointed out the importance of the position of chloro and nitro substituents for anticancer activity against A549 cell line. In particular, 2-chloro, 3-nitro, 4-nitro and 2,4-dichloro substitutions significantly enhanced anticancer activity, whereas other substitutions significantly decreased anticancer activity.
In order to determine whether the compounds were toxic or nontoxic to healthy cells, the effects of compounds 1-10 on L929 mouse fibroblast cells were investigated using MTT test. The selectivity index (SI) values of compounds 1, 5, 6 and 7 were also determined to compare their selectivity ( Table 1 ). The IC50 values of these compounds for L929 cell line were higher than their IC50 values for A549 cell line. This outcome indicated that their anticancer effects were selective. In particular, compounds 5 and 6 showed more selective anticancer activity than other compounds. After 24 h incubation, the apoptotic effects of compounds 1, 5, 6, 7 and cisplatin on A549 cells were analyzed based on Annexin V-Propidium iodide (PI) binding capacities in flow cytometry as depicted in Figure 3 . The early apoptotic effects of compounds 1, 5, 6, 7 and cisplatin on A549 cell line (at IC50 values) were determined as 4.7, 5.1, 7.3, 5.1 and 9.8% respectively, whilst their late apoptotic effects were determined as 3.7, 2.0, 4.9, 3.3 and 3.5%, respectively (Table 2 and Figure 3 ). According to these findings, compound 6 showed more apoptotic (early and late) activity than compounds 1, 5 and 7. The results indicated that p-nitro substituent significantly enhanced apoptotic activity against A549 cell line. At least 10,000 cells were analyzed per sample, and quadrant analysis was performed.
CONCLUSION
In the current work, we described the synthesis of new thiosemicarbazone derivatives, which were investigated for their cytotoxic and apoptotic effects on A549 cell line. Compounds 5 and 6 were identified as the most potent anticancer agents in this series against A549 cell line with IC50 values of 4.3±0.61 µg/mL and 5.5±2.12 µg/mL, respectively. Compound 6 also induced apoptosis significantly when compared with other compounds. Further studies are needed to enlighten the exact mechanism of action for the evaluation of compounds 5 and 6 as therapeutic agents for the treatment of NSCLC.
MATERIALS AND METHODS

Chemistry
All reagents purchased from commercial suppliers were used without further purification. The MP90 digital melting point apparatus (Mettler Toledo, Ohio, USA) was used to determine the melting points (M.p.) of the compounds. IR spectra were recorded on an IRPrestige-21 Fourier Transform Infrared spectrophotometer (Shimadzu, Tokyo, Japan). 1 H NMR and 13 C NMR spectra were recorded on a Varian Mercury-400 FT-NMR spectrometer (Agilent, Palo Alto, CA, USA). HRMS spectra were recorded on a Shimadzu LCMS-IT-TOF system (Shimadzu, Kyoto, Japan). [21] A mixture of 4-cyanophenyl isothiocyanate (0.1 mol) and hydrazine hydrate (0.2 mol) in ethanol (30 mL) was stirred at room temperature for 4 h and then filtered. The residue was crystallized from ethanol.
General procedure for the synthesis of the compounds 4-(4-Cyanophenyl)thiosemicarbazide
4-(4-Cyanophenyl)-1-[(5-arylfuran-2-yl)methylene]thiosemicarbazides (1-10)
A mixture of 4-(4-cyanophenyl)thiosemicarbazide (0.01 mol) and 5-arylfurfural (0.01 mol) was refluxed in ethanol for 8 h, filtered and crystallized from ethanol. 
4-(4-Cyanophenyl)-1-[(5-(2-chlorophenyl)furan-2-yl)methylene]thiosemicarbazide (1)
M
4-(4-Cyanophenyl)-1-[(5-(2-nitrophenyl)furan-2-yl)methylene]thiosemicarbazide (4)
4-(4-Cyanophenyl)-1-[(5-(3-nitrophenyl)furan-2-yl)methylene]thiosemicarbazide (5)
4-(4-Cyanophenyl)-1-[(5-(4-nitrophenyl)furan-2-yl)methylene]thiosemicarbazide (6)
4-(4-Cyanophenyl)-1-[(5-(2,4-dichlorophenyl)furan-2-yl)methylene]thiosemicarbazide (7)
4-(4-Cyanophenyl)-1-[(5-(3,4-dichlorophenyl)furan-2-yl)methylene]thiosemicarbazide (8)
Biochemistry
Cell culture and drug treatment
Cell lines were obtained from American Type Culture Collection (ATCC). A549 human lung adenocarcinoma and L929 mouse fibroblast cells were cultured and drug treatments were carried out as previously described [22] .
MTT assay
MTT assay was performed as previously described in the literature [22] with small modifications [20] . Cisplatin was used as a positive control. The SI values were also calculated according to the formula [23] below:
SI= IC50 for normal cell line / IC50 for cancerous cell line
Flow cytometric analyses of apoptosis
After the incubation of A549 cells with compounds 1, 5, 6, 7 and cisplatin at IC50 concentrations, phosphatidylserine externalization, which indicates early apoptosis, was detected using FITC Annexin V Apoptosis Detection Kit (BD Pharmingen, San Jose, CA, USA) on a BD FACSAria flow cytometer for 24 h. Annexin V staining protocol was applied according to the manufacturer's instructions (BD Pharmingen, San Jose, CA, USA) and analyzed by a BD FACSAria flow cytometer using FACSDiva version 6.1.1 software (BD Biosciences, San Jose, CA, USA).
